CISD2基因对膀胱癌预后和诊断的系统性分析
Systematic Analysis of CISD2 Gene on the Prognosis and Diagnosis of Bladder Cancer
DOI: 10.12677/ACM.2023.131107, PDF,    科研立项经费支持
作者: 于 鹏:青岛大学附属医院泌尿外科,山东 青岛;山东威海市妇幼保健院,山东 威海;贺天珍:南通大学特种医学研究院,江苏 南通;李兆峰, 赵 凯, 张宗亮, 尹心宝, 王振林, 杨 瀚, 李雪禹, 王庆雷, 王 科*:青岛大学附属医院泌尿外科,山东 青岛;张玉莲:青岛大学附属医院妇科,山东 青岛
关键词: 膀胱癌CISD2TCGA预后诊断Bladder Cancer CISD2 TCGA Prognosis Diagnosis
摘要: 目的:研究CISD2在膀胱癌(bladder cancer, BLCA)中的表达水平与生存预后的关系,预测患者的生存期,并分析CISD2的表达水平与免疫细胞浸润的相关性,从而研究该基因对肿瘤进展的影响。方法:用R分析CISD2在TCGA-BLCA数据库中的mRNA表达水平和临床数据,并对CISD2在膀胱癌中的共表达基因进行功能和信号通路富集分析。进一步用R语言分析CISD2与免疫细胞浸润的关系。结果:生物信息学分析表明CISD2在膀胱癌组织中表达水平显著高于相对应的癌周正常膀胱组织(P < 0.001)。CISD2的表达与Th2 cells、Th1 cells、aDC、NK CD56dm cells、T helper cells、Tgd、Neutrophils、Macrophages等免疫细胞浸润呈正相关关系,与pDC、NK CD56bright cells、Mast cells及B cells的浸润水平呈负相关关系。结论:CISD2在BLCA中可能与不良预后相关,并可能为BLCA的诊断和治疗提供新分子靶点。
Abstract: Objective: To investigate the relationship between CISD2 expression level and survival prognosis, and predict the survival time of patients in bladder cancer (BLCA), we analyzed the correlation be-tween CISD2 expression level and immune cell infiltration. Consequently, the effect of CISD2 on the development of tumor was studied. Methods: The mRNA expression profile and clinical data of CISD2 were obtained from TCGA-BLCA database by using R language. The function and signal path-way enrichment analysis of CISD2 and co-expressed genes in bladder cancer were further analyzed by using R language. The relationship between CISD2 expression and immune cell infiltration was further analyzed by using R language. Results: Compared with the normal group, CISD2 expression in BLCA was significantly increased (P < 0.001). High CISD2 expression predicted poor prognosis in BLCA. CISD2 expression level has significant positive correlations with infiltrating levels of Th2 cells, Th1 cells, aDC, NK CD56dm cells, T helper cells, Tgd, Neutrophils and Macrophages cells. In addition, CISD2 expression level has significant negative correlation with pDC, NK CD56 bright cells, Mast cells and B cells. Conclusion: This study implied that CISD2 may be a promising prognosis predictor and potential therapy target for BLAC patients.
文章引用:于鹏, 贺天珍, 李兆峰, 赵凯, 张宗亮, 尹心宝, 王振林, 张玉莲, 杨瀚, 李雪禹, 王庆雷, 王科. CISD2基因对膀胱癌预后和诊断的系统性分析[J]. 临床医学进展, 2023, 13(1): 737-748. https://doi.org/10.12677/ACM.2023.131107

参考文献

[1] Witjes, J.A., Bruins, H.M., Cathomas, R., et al. (2021) European Association of Urology Guidelines on Muscle-Invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. European Urology, 79, 82-104. [Google Scholar] [CrossRef] [PubMed]
[2] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[3] Kamat, A.M., Hahn, N.M., Efstathiou, J.A., et al. (2016) Bladder Cancer. The Lancet (London, England), 388, 2796- 2810. [Google Scholar] [CrossRef
[4] Knowles, M.A. and Hurst, C.D. (2015) Molecular Biology of Bladder Cancer: New Insights into Pathogenesis and Clinical Diver-sity. Nature Reviews. Cancer, 15, 25-41. [Google Scholar] [CrossRef] [PubMed]
[5] Stein, J.P., Lieskovsky, G., Cote, R., et al. (2001) Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 19, 666-675. [Google Scholar] [CrossRef
[6] Madersbacher, S., Hochreiter, W., Burkhard, F., et al. (2003) Radical Cystectomy for Bladder Cancer Today—A Homogeneous Series without Neoadjuvant Therapy. Journal of Clin-ical Oncology: Official Journal of the American Society of Clinical Oncology, 21, 690-696. [Google Scholar] [CrossRef
[7] Lopez-Beltran, A., Cimadamore, A., Blanca, A., et al. (2021) Im-mune Checkpoint Inhibitors for the Treatment of Bladder Cancer. Cancers, 13, 131. [Google Scholar] [CrossRef] [PubMed]
[8] Sharma, P., Retz, M., Siefker-Radtke, A., et al. (2017) Nivolumab in Metastatic Urothelial Carcinoma after Platinum Therapy (CheckMate 275): A Multicentre, Single-Arm, Phase 2 Trial. The Lancet. Oncology, 18, 312-322. [Google Scholar] [CrossRef
[9] Mariathasan, S., Turley, S.J., Nickles, D., et al. (2018) TGFβ Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells. Nature, 554, 544-548. [Google Scholar] [CrossRef] [PubMed]
[10] Yang, L., Hong, S., Wang, Y., et al. (2016) A Novel Prognostic Score Model Incorporating CDGSH Iron Sulfur Domain2 (CISD2) Predicts Risk of Disease Progression in Laryngeal Squa-mous Cell Carcinoma. Oncotarget, 7, 22720- 22732. [Google Scholar] [CrossRef] [PubMed]
[11] Yeh, C.-H., Shen, Z.-Q., Hsiung, S.-Y., et al. (2019) Cisd2 Is Essential to Delaying Cardiac Aging and to Maintaining Heart Func-tions. PLoS Biology, 17, e3000508. [Google Scholar] [CrossRef] [PubMed]
[12] Sun, A.-G., Meng, F.-G. and Wang, M.-G. (2017) CISD2 Promotes the Proliferation of Glioma Cells via Suppressing Beclin-1-Mediated Au-tophagy and Is Targeted by microRNA‑449a. Molecular Medicine Reports, 16, 7939-7948. [Google Scholar] [CrossRef] [PubMed]
[13] Sun, Y., Jiang, Y., Huang, J., et al. (2017) CISD2 Enhances the Chemosensitivity of Gastric Cancer through the Enhancement of 5-FU-Induced Apoptosis and the Inhibition of Autoph-agy by AKT/mTOR Pathway. Cancer Medicine, 6, 2331-2346. [Google Scholar] [CrossRef] [PubMed]
[14] Wang, C.-H., Chen, Y.-F., Wu, C.-Y., et al. (2014) Cisd2 Modulates the Differentiation and Functioning of Adipocytes by Regulating Intracellular Ca2+ Homeostasis. Human Molecular Genetics, 23, 4770-4785. [Google Scholar] [CrossRef] [PubMed]
[15] Zhu, Q.-Q., Tian, L., Li, D.-L., et al. (2020) Elevated CISD2 Expression Predicts Poor Diagnosis and Promotes Invasion and Migration of Prostate Cancer Cells. European Review for Medical and Pharmacological Sciences, 24, 6597- 6604.
[16] Mozzillo, E., Delvecchio, M., Carella, M., et al. (2014) A Novel CISD2 Intragenic Deletion, Optic Neuropathy and Platelet Aggregation Defect in Wolfram Syndrome Type 2. BMC Medical Genetics, 15, 88. [Google Scholar] [CrossRef] [PubMed]
[17] Liu, L., Xia, M., Wang, J., et al. (2014) CISD2 Expression Is a Novel Marker Correlating with Pelvic Lymph Node Metastasis and Prognosis in Patients with Early-Stage Cervical Can-cer. Medical Oncology (Northwood, London, England), 31, 183. [Google Scholar] [CrossRef] [PubMed]
[18] Chen, B., Shen, S., Wu, J., et al. (2015) CISD2 Associated with Proliferation Indicates Negative Prognosis in Patients with Hepatocellular Carcinoma. International Journal of Clinical and Experimental Pathology, 8, 13725-13738.
[19] Wang, L., Ouyang, F., Liu, X., et al. (2016) Overexpressed CISD2 Has Prognostic Value in Human Gastric Cancer and Promotes Gastric Cancer Cell Proliferation and Tumorigenesis via AKT Signaling Pathway. Oncotarget, 7, 3791-3805. [Google Scholar] [CrossRef] [PubMed]
[20] Li, S.-M., Chen, C.-H., Chen, Y.-W., et al. (2017) Upregulation of CISD2 Augments ROS Homeostasis and Contributes to Tumorigenesis and Poor Prognosis of Lung Adenocarcinoma. Scientific Reports, 7, Article No. 11893. [Google Scholar] [CrossRef] [PubMed]
[21] Chen, Y.-F., Wu, C.-Y., Kirby, R., et al. (2010) A Role for the CISD2 Gene in Lifespan Control and Human Disease. Annals of the New York Academy of Sciences, 1201, 58-64. [Google Scholar] [CrossRef] [PubMed]
[22] Kim, E.H., Shin, D., Lee, J., et al. (2018) CISD2 Inhibition Overcomes Resistance to Sulfasalazine-Induced Ferroptotic Cell Death in Head and Neck Cancer. Cancer Letters, 432, 180-190. [Google Scholar] [CrossRef] [PubMed]
[23] 刘璐欣, 何勉, 刘军秀, 等. CISD2在早期宫颈腺癌中的表达和临床意义[J]. 中山大学学报(医学科学版), 2015, 36(5): 728-733.
[24] 刘壮凯, 白静慧, 张瑞山, 等. CISD2在乳腺癌组织中的表达及其对人乳腺癌MCF-7细胞增殖与侵袭的影响[J]. 解剖科学进展, 2020, 26(2): 140-142.